Bloomberg Talks
Novartis AG CEO Talks Medicinal Sales
Apr 23, 2024
Novartis AG CEO discusses strong performance of established medicines and new drug launches. They explore market acceptance of a new cancer drug, company growth drivers, Swiss cultural identity, global operations, and strategic acquisitions in the pharmaceutical industry.
09:54
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Novartis focuses on strong growth drivers like established medicines and recent launches, anticipating global expansion and market opportunities.
- Balancing tradition with international presence, Novartis aligns strategic capital allocation for sustained growth and maintains a world-class pharmaceutical competitive culture.
Deep dives
Optimism and Growth in Novartis Business Outlook
Novartis CEO expresses confidence in the company's performance, highlighting strong growth drivers such as established medicines and recent launches like Kasymta and Kaskali. The CEO emphasizes positive geographical performance across various regions, reflecting optimism for future years. Specifically discussing the cancer drug Pluvicto, the CEO remains confident in its outlook despite a supply disruption, foreseeing global expansion and potential market opportunities in new cancer settings.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
